NADAC acquisition cost data for VIVITROL 380 MG VIAL-DILUENT. This is a brand-name medication — generic alternatives may be available at lower prices.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 65757030001 | $1,446.85 | 2022-04-01 | Rx |
| 65757030001 | $1,446.85 | 2022-04-01 | Rx |
| 65757030001 | $1,446.85 | 2022-04-01 | Rx |
| 65757030001 | $1,446.85 | 2022-04-01 | Rx |
| 65757030001 | $1,446.85 | 2022-04-01 | Rx |
| 65757030001 | $1,446.85 | 2022-04-01 | Rx |
| 65757030001 | $1,446.85 | 2022-04-01 | Rx |
| 65757030001 | $1,446.85 | 2022-04-01 | Rx |
| 65757030001 | $1,446.85 | 2022-04-01 | Rx |
| 65757030001 | $1,446.85 | 2022-04-01 | Rx |
Generic: Naltrexone Microspheres | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $36.0M | 26,676 | 6,694 | $1,337.57 |
| 2020 | $36.7M | 26,136 | 6,439 | $1,383.77 |
| 2021 | $43.3M | 29,526 | 6,999 | $1,461.92 |
| 2022 | $50.7M | 32,755 | 7,654 | $1,545.63 |
| 2023 | $62.2M | 37,159 | 8,594 | $1,669.62 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| New York | $6.4M | 3,784 | 809 |
| California | $5.3M | 3,169 | 730 |
| Massachusetts | $5.3M | 3,213 | 674 |
| Pennsylvania | $4.4M | 2,640 | 635 |
| Ohio | $3.8M | 2,282 | 584 |
| Michigan | $2.9M | 1,743 | 416 |
| Missouri | $2.4M | 1,410 | 294 |
| Kentucky | $2.4M | 1,392 | 407 |
| Indiana | $2.0M | 1,213 | 296 |
| New Jersey | $1.9M | 1,148 | 284 |
| Arizona | $1.9M | 1,133 | 255 |
| Connecticut | $1.6M | 956 | 198 |
| Illinois | $1.6M | 985 | 248 |
| North Carolina | $1.6M | 948 | 347 |
| Wisconsin | $1.4M | 839 | 182 |
| Maryland | $1.4M | 844 | 209 |
| Colorado | $1.2M | 736 | 162 |
| Washington | $1.2M | 694 | 191 |
| Florida | $1.2M | 697 | 215 |
| Tennessee | $1.1M | 665 | 166 |
| Virginia | $1.1M | 655 | 157 |
| West Virginia | $808.5K | 479 | 139 |
| Utah | $759.4K | 459 | 86 |
| New Hampshire | $632.2K | 375 | 87 |
| Minnesota | $624.7K | 374 | 66 |
| South Carolina | $561.9K | 336 | 69 |
| Oregon | $501.1K | 307 | 77 |
| Texas | $482.9K | 284 | 70 |
| New Mexico | $481.7K | 288 | 78 |
| Louisiana | $417.6K | 251 | 94 |
| Delaware | $410.4K | 244 | 56 |
| Alaska | $378.0K | 220 | 64 |
| Rhode Island | $370.3K | 228 | 52 |
| Georgia | $368.8K | 224 | 61 |
| Maine | $356.5K | 213 | 49 |
| Vermont | $351.8K | 207 | 38 |
| North Dakota | $327.6K | 195 | 42 |
| Kansas | $290.3K | 174 | 48 |
| Oklahoma | $260.1K | 155 | 42 |
| Arkansas | $198.7K | 115 | 29 |
| Alabama | $194.3K | 116 | 36 |
| Idaho | $193.9K | 117 | 37 |
| Nebraska | $186.4K | 111 | 30 |
| District of Columbia | $162.8K | 99 | 21 |
| Nevada | $139.7K | 82 | 19 |
| Montana | $110.7K | 65 | 14 |
| Wyoming | $103.5K | 61 | 12 |
| Iowa | $102.7K | 60 | 14 |
| Hawaii | $92.2K | 54 | 13 |
| Mississippi | $90.5K | 53 | 16 |
| South Dakota | $51.7K | 30 | N/A |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.
Explore More Data Tools
For adjacent public-data tools, methodology notes, and network updates, visit DataPeek Facts.